217 related articles for article (PubMed ID: 37762931)
1. Advances in Targeted Therapy for the Treatment of Cervical Cancer.
Watkins DE; Craig DJ; Vellani SD; Hegazi A; Fredrickson KJ; Walter A; Stanbery L; Nemunaitis J
J Clin Med; 2023 Sep; 12(18):. PubMed ID: 37762931
[TBL] [Abstract][Full Text] [Related]
2. The current status of immunotherapy for cervical cancer.
Orbegoso C; Murali K; Banerjee S
Rep Pract Oncol Radiother; 2018; 23(6):580-588. PubMed ID: 30534022
[TBL] [Abstract][Full Text] [Related]
3. Towards Novel Gene and Cell Therapy Approaches for Cervical Cancer.
Polten R; Kutle I; Hachenberg J; Klapdor R; Morgan M; Schambach A
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612258
[TBL] [Abstract][Full Text] [Related]
4. Advances in immunotherapy for cervical cancer.
Grau-Bejar JF; Garcia-Duran C; Garcia-Illescas D; Mirallas O; Oaknin A
Ther Adv Med Oncol; 2023; 15():17588359231163836. PubMed ID: 37007635
[TBL] [Abstract][Full Text] [Related]
5. Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review.
Boussios S; Seraj E; Zarkavelis G; Petrakis D; Kollas A; Kafantari A; Assi A; Tatsi K; Pavlidis N; Pentheroudakis G
Crit Rev Oncol Hematol; 2016 Dec; 108():164-174. PubMed ID: 27931835
[TBL] [Abstract][Full Text] [Related]
6. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
7. Review Article: Immune Landscape and Immunotherapy Options in Cervical Carcinoma.
Kousar K; Ahmad T; Naseer F; Kakar S; Anjum S
Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139618
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational research.
Lee SJ; Yang A; Wu TC; Hung CF
J Gynecol Oncol; 2016 Sep; 27(5):e51. PubMed ID: 27329199
[TBL] [Abstract][Full Text] [Related]
9. Top advances of the year: Cervical cancer.
Podwika SE; Duska LR
Cancer; 2023 Mar; 129(5):657-663. PubMed ID: 36609769
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy and Its Development for Gynecological (Ovarian, Endometrial and Cervical) Tumors: From Immune Checkpoint Inhibitors to Chimeric Antigen Receptor (CAR)-T Cell Therapy.
Schepisi G; Casadei C; Toma I; Poti G; Iaia ML; Farolfi A; Conteduca V; Lolli C; Ravaglia G; Brighi N; Altavilla A; Martinelli G; De Giorgi U
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33671294
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy: an evolving paradigm in the treatment of advanced cervical cancer.
Eskander RN; Tewari KS
Clin Ther; 2015 Jan; 37(1):20-38. PubMed ID: 25592089
[TBL] [Abstract][Full Text] [Related]
12. Cervical Cancer Immunotherapy: Facts and Hopes.
Ferrall L; Lin KY; Roden RBS; Hung CF; Wu TC
Clin Cancer Res; 2021 Sep; 27(18):4953-4973. PubMed ID: 33888488
[TBL] [Abstract][Full Text] [Related]
13. From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?
Madden DL
Curr Oncol Rep; 2018 Feb; 20(1):8. PubMed ID: 29411148
[TBL] [Abstract][Full Text] [Related]
14. Advances in immunotherapy for cervical cancer: recent developments and future directions.
Sherer MV; Kotha NV; Williamson C; Mayadev J
Int J Gynecol Cancer; 2022 Mar; 32(3):281-287. PubMed ID: 35256414
[TBL] [Abstract][Full Text] [Related]
15. Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody.
Peng S; Ferrall L; Gaillard S; Wang C; Chi WY; Huang CH; Roden RBS; Wu TC; Chang YN; Hung CF
mBio; 2021 Jan; 12(1):. PubMed ID: 33468698
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy and Systemic Therapy in Metastatic/Recurrent Endometrial and Cervical Cancers.
Lima J; Ali Z; Banerjee S
Clin Oncol (R Coll Radiol); 2021 Sep; 33(9):608-615. PubMed ID: 34312021
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of combination therapy with ISA101 vaccine for the treatment of human papillomavirus-induced cervical cancer.
Ding H; Zhang J; Zhang F; Xu Y; Yu Y; Liang W; Li Q
Front Oncol; 2022; 12():990877. PubMed ID: 36300095
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy as a Therapeutic Strategy for Gastrointestinal Cancer-Current Treatment Options and Future Perspectives.
Koustas E; Trifylli EM; Sarantis P; Papadopoulos N; Karapedi E; Aloizos G; Damaskos C; Garmpis N; Garmpi A; Papavassiliou KA; Karamouzis MV; Papavassiliou AG
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743107
[TBL] [Abstract][Full Text] [Related]
19. The Roles of Programmed Cell Death Ligand-1/ Programmed Cell Death-1 (PD-L1/PD-1) in HPV-induced Cervical Cancer and Potential for their Use in Blockade Therapy.
Zhang L; Zhao Y; Tu Q; Xue X; Zhu X; Zhao KN
Curr Med Chem; 2021; 28(5):893-909. PubMed ID: 32003657
[TBL] [Abstract][Full Text] [Related]
20. Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer.
Luo C; Wang P; He S; Zhu J; Shi Y; Wang J
Front Oncol; 2022; 12():919072. PubMed ID: 35795050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]